1. Home
  2. KPTI vs ALOT Comparison

KPTI vs ALOT Comparison

Compare KPTI & ALOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • ALOT
  • Stock Information
  • Founded
  • KPTI 2008
  • ALOT 1969
  • Country
  • KPTI United States
  • ALOT United States
  • Employees
  • KPTI N/A
  • ALOT N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • ALOT Computer peripheral equipment
  • Sector
  • KPTI Health Care
  • ALOT Technology
  • Exchange
  • KPTI Nasdaq
  • ALOT Nasdaq
  • Market Cap
  • KPTI 121.2M
  • ALOT 110.1M
  • IPO Year
  • KPTI 2013
  • ALOT N/A
  • Fundamental
  • Price
  • KPTI $0.90
  • ALOT $13.27
  • Analyst Decision
  • KPTI Strong Buy
  • ALOT
  • Analyst Count
  • KPTI 4
  • ALOT 0
  • Target Price
  • KPTI $5.00
  • ALOT N/A
  • AVG Volume (30 Days)
  • KPTI 770.4K
  • ALOT 18.1K
  • Earning Date
  • KPTI 10-31-2024
  • ALOT 09-16-2024
  • Dividend Yield
  • KPTI N/A
  • ALOT N/A
  • EPS Growth
  • KPTI N/A
  • ALOT 591.76
  • EPS
  • KPTI N/A
  • ALOT 0.83
  • Revenue
  • KPTI $145,668,000.00
  • ALOT $150,643,000.00
  • Revenue This Year
  • KPTI $6.41
  • ALOT N/A
  • Revenue Next Year
  • KPTI $11.85
  • ALOT N/A
  • P/E Ratio
  • KPTI N/A
  • ALOT $16.29
  • Revenue Growth
  • KPTI N/A
  • ALOT 0.29
  • 52 Week Low
  • KPTI $0.62
  • ALOT $11.79
  • 52 Week High
  • KPTI $1.95
  • ALOT $18.83
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 58.85
  • ALOT 40.99
  • Support Level
  • KPTI $0.71
  • ALOT $12.86
  • Resistance Level
  • KPTI $0.94
  • ALOT $13.75
  • Average True Range (ATR)
  • KPTI 0.06
  • ALOT 0.52
  • MACD
  • KPTI 0.02
  • ALOT -0.05
  • Stochastic Oscillator
  • KPTI 66.12
  • ALOT 32.59

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About ALOT AstroNova Inc.

AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.

Share on Social Networks: